Wall Street analyst estimates for Cardiff Oncology, Inc. (CRDF): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.14 | ||
| 2026-08-11 | $-0.14 | $-0.12 | -17.0% |
| 2026-05-14 | $-0.18 | $-0.13 | -38.5% |
| 2026-02-24 | $-0.11 | $-0.18 | +38.9% |
| 2025-11-06 | $-0.17 | $-0.20 | +15.0% |
| 2025-07-29 | $-0.21 | $-0.19 | -10.5% |
| 2025-05-08 | $-0.20 | $-0.19 | -5.3% |
| 2025-02-27 | $-0.21 | $-0.26 | +19.2% |
Valuation Ratios
| Price / Book | 3.63 |
| EV / EBITDA | -1.93 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $381000 | $505000 | $378000 | $244632 | $366000 | $359000 | $386000 | $488000 | $683000 | $593000 |
| Cost of Revenue | $1.7M | $1.8M | $597000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$1.3M | -$1.3M | -$219000 | $244632 | $366000 | $359000 | $386000 | $488000 | $683000 | $593000 |
| Research & Development | $15.0M | $7.9M | $8.2M | $11.2M | $11.2M | $17.4M | $27.1M | $32.9M | $36.9M | $35.3M |
| Selling, General & Admin | $23.0M | $14.2M | $8.0M | $5.8M | $8.2M | $11.8M | $13.2M | $13.0M | $12.5M | $14.2M |
| Operating Expenses | $38.0M | $22.1M | $16.2M | $16.9M | $19.5M | $29.2M | $40.3M | $45.9M | $49.3M | $49.6M |
| Operating Income | -$40.1M | -$25.6M | -$17.1M | -$16.7M | -$19.1M | -$28.9M | -$39.9M | -$45.4M | -$48.7M | -$49.0M |
| EBITDA | -$36.8M | -$22.8M | -$15.7M | -$15.9M | -$18.8M | -$27.8M | -$38.5M | -$41.0M | -$45.0M | -$44.9M |
| Interest Expense | $1.4M | $1.0M | $25409 | 0 | $2000 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$39.2M | -$24.9M | -$16.5M | -$16.4M | -$19.3M | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| Income Tax | -$296000 | $716000 | $617643 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$39.2M | -$24.9M | -$16.5M | -$16.4M | -$19.3M | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| EPS | $-93.54 | $-51.71 | $-7.06 | $-2.70 | $-1.08 | $-0.73 | $-0.89 | $-0.93 | $-0.95 | $-0.69 |
| EPS (Diluted) | $-93.22 | $-51.71 | $-7.06 | $-2.70 | $-1.08 | $-0.73 | $-0.89 | $-0.93 | $-0.95 | $-0.69 |
| Shares Outstanding (Diluted) | $420568 | $481665 | $2.3M | $6.0M | $20.9M | $39.0M | $43.6M | $44.7M | $47.6M | $66.8M |
Price
| Price | $1.35 |
| Market Cap | $104M |
| Exchange | NASDAQ |
| Country | US |
Related companies: APLT · CRBP · ELTX · FBRX · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of CRDF: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks